Equillium, Inc. (EQ)

USD 0.63

(-5.3%)

Market Cap (In USD)

22.14 Million

Revenue (In USD)

36.08 Million

Net Income (In USD)

-13.33 Million

Avg. Volume

134.28 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.6-3.25
PE
-
EPS
-
Beta Value
1.826
ISIN
US29446K1060
CUSIP
29446K106
CIK
1746466
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Bruce D. Steel C.F.A.
Employee Count
-
Website
https://equilliumbio.com
Ipo Date
2018-10-12
Details
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.